Impact of ribavirin dose on retreatment of chronic hepatitis C patients

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

298

HTML

2077

Figures (1-2)

238

Tables (1-2)

242

Sum=2855

Jun 21, 2012 (publication date) through Jan 25, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jun 21, 2012; 18(23): 2966-2972
Published online Jun 21, 2012. doi: 10.3748/wjg.v18.i23.2966

Table 2 Treatment characteristics

	No. of patients, n (%)	SVR (%)
Overall population	62 (100)	42
Type of PEG-IFN (retreatment)
PEG-IFN-α2a	43 (69)	40
PEG-IFN-α2b	19 (31)	47
RBV ≥ 13.3 mg/kg per day	34 (54)	35
RBV ≥ 15.2 mg/kg per day	10 (16)	70
Treatment duration 24 wk longer than previous course	31 (51)	53
Patients with RBV ≥ 15.2 mg/kg per day and 24 wk longer duration	6 (10)	67

Sustained virological response (SVR) according to different types of pegylated interferon (PEG-IFN), dose of ribavirin (RBV) and duration of therapy.

Citation: Stern C, Martinot-Peignoux M, Ripault MP, Boyer N, Castelnau C, Valla D, Marcellin P. Impact of ribavirin dose on retreatment of chronic hepatitis C patients. World J Gastroenterol 2012; 18(23): 2966-2972
URL: https://www.wjgnet.com/1007-9327/full/v18/i23/2966.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i23.2966